Clinical Trials

The physicians and staff at Eastern Urological Associates strive to remain abreast of advances in medical treatment of urologic conditions. Part of our commitment to this is by participating in national recognized clinical trials. Clinical trials are used to determine whether new drugs or treatments are safe and effective, as well as offering patients the opportunity to have access to such treatments prior to them being available to the public. The EUA staff has been active in clinical trials since 2004.

Participating in a clinical trial is different from receiving routine medical care. Trial participants are monitored very closely by EUA’s clinical research staff. Our mission to our study patients is to treat them like family, and offer them a specialized level of care that they would not receive in routine medical care. Patient safety is our utmost priority, and our clinical trial participants have 24-hour access to study staff. It is important to consider that some trials may not directly benefit the study participant, but can help to further medical knowledge and improve medical care for future generations. Our staff is happy to discuss trial options with you, and provide you with resources to assist you in deciding whether clinical trial participation is a good option for you. Trial participation is voluntary.


Study Name:  ARCHES
Indication:  Metastatic Prostate Cancer
Sponsor:  Astellas
Description:  A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Study Name:  TRUMPET
Indication:  Registry Study for patients with Castrate-Resistant Prostate Cancer (CRPC)
Sponsor:  Astellas
Description:  A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States

Study Name:  Hematuria Specimen Collection Study
Indication:  Hematuria (blood in urine)
Sponsor:  MDxHealth, Inc.
Description:  Non-invasive, Urine-based AssureMDx Feasibility Testing on Patients Undergoing Initial Diagnostic Evaluation for Bladder Cancer


Study Name:  RVT-901-3003
Indication:  Overactive Bladder
Sponsor:  Urovant Sciences
Description:  An International Phase 3, Randomized, Double-blind, Placebo and Active (Tolterodine) Controlled Multicenter to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder


Study Name:  SPARTAN
Indication:  Prostate Cancer
Sponsor:  Janssen
Description:  A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of ARN-509 in Men with Non-Metastatic Castration-Resistant Prostate Cancer

Study Name:  LIRIS (201025-002)
Indication:  Interstitial Cystitis
Sponsor:  Allergan
Description:  A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS 400 mg in Females with Interstitial Cystitis

Study Name:  BHR-510-101
Indication: Low Testosterone
Sponsor:  BHR Pharma
Description:  A Study to Compare Saliva Testosterone Levels to Serum Free and Total Testosterone Levels in Adult Men

Study Name:  CL1401
Indication:  Urinary Catheter Encrustation
Sponsor:  NovaBay Pharmaceuticals
Description:  A Multicenter, Randomized, Double-blind Three-Arm Efficacy Study of Auriclosene Irrigation Solution on Indwelling Urinary Catheter Patency

For more information on current clinical trials being conducted at Eastern Urological Associates, please contact:

Carla Griffin, RN, BSN, CCRC